KR102730367B1 - 그룹 a 스트렙토코쿠스 백신 - Google Patents

그룹 a 스트렙토코쿠스 백신 Download PDF

Info

Publication number
KR102730367B1
KR102730367B1 KR1020167031477A KR20167031477A KR102730367B1 KR 102730367 B1 KR102730367 B1 KR 102730367B1 KR 1020167031477 A KR1020167031477 A KR 1020167031477A KR 20167031477 A KR20167031477 A KR 20167031477A KR 102730367 B1 KR102730367 B1 KR 102730367B1
Authority
KR
South Korea
Prior art keywords
seq
terminus
peptide
derivative
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167031477A
Other languages
English (en)
Korean (ko)
Other versions
KR20160144455A (ko
Inventor
마니샤 판데이
마이클 배츠로프
마이클 굿
Original Assignee
그리피스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901382A external-priority patent/AU2014901382A0/en
Application filed by 그리피스 유니버시티 filed Critical 그리피스 유니버시티
Priority to KR1020237007349A priority Critical patent/KR102744193B1/ko
Publication of KR20160144455A publication Critical patent/KR20160144455A/ko
Application granted granted Critical
Publication of KR102730367B1 publication Critical patent/KR102730367B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167031477A 2014-04-15 2015-04-15 그룹 a 스트렙토코쿠스 백신 Active KR102730367B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237007349A KR102744193B1 (ko) 2014-04-15 2015-04-15 그룹 a 스트렙토코쿠스 백신

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014901382 2014-04-15
AU2014901382A AU2014901382A0 (en) 2014-04-15 Group a streptococcal vaccine
AU2014903042A AU2014903042A0 (en) 2014-08-06 Group a streptococcal vaccine
AU2014903042 2014-08-06
AU2014904453A AU2014904453A0 (en) 2014-11-05 Group a streptococcal vaccine
AU2014904453 2014-11-05
PCT/AU2015/050174 WO2015157820A1 (en) 2014-04-15 2015-04-15 Group a streptococcus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007349A Division KR102744193B1 (ko) 2014-04-15 2015-04-15 그룹 a 스트렙토코쿠스 백신

Publications (2)

Publication Number Publication Date
KR20160144455A KR20160144455A (ko) 2016-12-16
KR102730367B1 true KR102730367B1 (ko) 2024-11-15

Family

ID=54323282

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167031477A Active KR102730367B1 (ko) 2014-04-15 2015-04-15 그룹 a 스트렙토코쿠스 백신
KR1020237007349A Active KR102744193B1 (ko) 2014-04-15 2015-04-15 그룹 a 스트렙토코쿠스 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237007349A Active KR102744193B1 (ko) 2014-04-15 2015-04-15 그룹 a 스트렙토코쿠스 백신

Country Status (16)

Country Link
US (2) US10301362B2 (cg-RX-API-DMAC7.html)
EP (1) EP3131575B1 (cg-RX-API-DMAC7.html)
JP (2) JP2017513849A (cg-RX-API-DMAC7.html)
KR (2) KR102730367B1 (cg-RX-API-DMAC7.html)
CN (1) CN106794236B (cg-RX-API-DMAC7.html)
AU (1) AU2015246654B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016023915B1 (cg-RX-API-DMAC7.html)
CA (1) CA2945052C (cg-RX-API-DMAC7.html)
DK (1) DK3131575T3 (cg-RX-API-DMAC7.html)
IL (1) IL248266B (cg-RX-API-DMAC7.html)
MX (1) MX392514B (cg-RX-API-DMAC7.html)
MY (1) MY191217A (cg-RX-API-DMAC7.html)
NZ (1) NZ725212A (cg-RX-API-DMAC7.html)
SG (1) SG11201608380PA (cg-RX-API-DMAC7.html)
WO (1) WO2015157820A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201607355B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945052C (en) 2014-04-15 2023-05-02 Griffith University Group a streptococcus vaccine
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
SG11202001557PA (en) * 2017-08-23 2020-03-30 Univ Griffith Immunogenic peptide against group a streptococcus
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
KR102437436B1 (ko) * 2019-04-26 2022-08-30 주식회사 엠디헬스케어 스트렙토코커스 파이오제네스 세균 유래 단백질 및 이의 용도
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
BRPI0610093A2 (pt) * 2005-05-05 2008-12-09 Merck & Co Inc composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
EP2287189A1 (en) * 2006-07-07 2011-02-23 Intercell AG Small Streptococcus pyogenes antigens and their use
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
US8482298B2 (en) 2006-12-18 2013-07-09 Schrader Electronics Ltd. Liquid level and composition sensing systems and methods using EMF wave propagation
JP5653215B2 (ja) * 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
US20090162369A1 (en) * 2007-12-12 2009-06-25 Katin Helena Threse Nordstrom Synthetic chimeric peptides
SI2344523T1 (sl) * 2008-09-17 2016-06-30 Glaxosmithkline Biologicals S.A. Kombinirana GAS-cepiva in zdravila
CA2945052C (en) 2014-04-15 2023-05-02 Griffith University Group a streptococcus vaccine
SG11202001557PA (en) * 2017-08-23 2020-03-30 Univ Griffith Immunogenic peptide against group a streptococcus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Proceedings of the Tenth Global Vaccine Research Forum and Parallel Satellite Symposia, Immunization, Vaccines and Biologicals, WHO(2011.6.26.-29.)*
The Journal of Infectious Disease, 제187권, 1598-1608면(2003.5.15.)*
Vaccine, 제27권, 4923-4929면(2009)*

Also Published As

Publication number Publication date
IL248266B (en) 2021-09-30
IL248266A0 (en) 2016-11-30
NZ725212A (en) 2023-04-28
MX392514B (es) 2025-03-24
US10513544B2 (en) 2019-12-24
CA2945052C (en) 2023-05-02
KR20160144455A (ko) 2016-12-16
EP3131575B1 (en) 2024-05-08
EP3131575A4 (en) 2017-11-01
JP7072921B2 (ja) 2022-05-23
CA2945052A1 (en) 2015-10-22
US10301362B2 (en) 2019-05-28
US20170037087A1 (en) 2017-02-09
CN106794236B (zh) 2021-09-03
ZA201607355B (en) 2019-03-27
KR102744193B1 (ko) 2024-12-19
AU2015246654B2 (en) 2019-08-08
KR20230039751A (ko) 2023-03-21
JP2021042247A (ja) 2021-03-18
MX2016013277A (es) 2017-01-18
BR112016023915B1 (pt) 2024-03-12
MY191217A (en) 2022-06-09
WO2015157820A1 (en) 2015-10-22
SG11201608380PA (en) 2016-11-29
AU2015246654A1 (en) 2016-11-03
DK3131575T3 (da) 2024-05-21
EP3131575A1 (en) 2017-02-22
US20190256562A1 (en) 2019-08-22
CN106794236A (zh) 2017-05-31
JP2017513849A (ja) 2017-06-01
BR112016023915A2 (pt) 2017-10-17

Similar Documents

Publication Publication Date Title
US10513544B2 (en) Group A streptococcus vaccine
RU2735101C2 (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
US12383630B2 (en) Immunogenic peptide against group a Streptococcus
JP7181208B2 (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
WO2017070735A1 (en) Liposomal vaccine
KR20210010882A (ko) 연쇄구균 독성 쇼크 증후군
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
HK1238144A1 (en) Group a streptococcus vaccine
HK1238144B (zh) A群链球菌疫苗
US20250332246A1 (en) Enhanced expression via autotransporters
US20180243392A1 (en) Cs21 and lnga protein vaccines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001702; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230807

Effective date: 20240926

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20240926

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2016 7031477

Appeal request date: 20230807

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023101001702

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601